Trial reportJapanese journal of clinical oncology2026
A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY).
Kota Kawabata, Koichi Yasuda, Satoaki Nakamura, Yoshitaka Honma, Ryusuke Suzuki, Yuri Ueda, Satoshi Saito, Kazuto Matsuura, Nobuhiro Hanai, Naoki Nakamura and 6 more
Abstract readMulticenter StudyClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraphTrial report in Japanese journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Kota KawabataJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.ORCID 0009-0006-5057-7985 Koichi YasudaDepartment of Radiation Oncology, Hokkaido University Hospital, North-15 West-7, Sapporo, Hokkaido 060-8638, Japan.ORCID 0000-0002-6333-3051 Satoaki NakamuraDivision of Radiation Oncology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka 573-1010, Japan.
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.ORCID 0000-0002-4209-4493 Ryusuke SuzukiDepartment of Medical Physics, Hokkaido University Hospital, North-15 West-7, Sapporo, Hokkaido 060-8638, Japan.ORCID 0000-0002-4635-9487 Yuri UedaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
Satoshi SaitoDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
Kazuto MatsuuraDepartment of Head and Neck Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan.ORCID 0000-0003-2524-8283 Naoki NakamuraDepartment of Radiation Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan.
Junki MizusawaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.ORCID 0000-0001-8123-5298 Keita SasakiJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.ORCID 0009-0005-5100-3863 Haruhiko FukudaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Takashi MizowakiDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.ORCID 0000-0002-8135-8746 Naomi KiyotaDepartment of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.ORCID 0000-0001-8021-6116 Head and Neck Cancer Study Group and the Radiation Therapy Study Group of the Japan Clinical Oncology Group
Funding
Japan Agency for Medical Research and Development JP25ck0106080National Cancer Center Research and Development Fund 2023-J-03
6 · The paper itselfAbstract
Chemoradiotherapy (CRT) with high-dose cisplatin (100 mg/m2) is the standard treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, this regimen is often intolerable in elderly patients because of its toxicity, and the optimal treatment for those unfit for high-dose cisplatin remains unclear. CRT with weekly cisplatin (40 mg/m2) has been developed as a more tolerable alternative and has demonstrated comparable efficacy with reduced toxicity in several trials involving nonelderly patients. We therefore designed a multicenter, randomized phase III trial (JCOG2405) to confirm the superiority of CRT with weekly cisplatin over radiotherapy alone in patients aged ≥70 years with locally advanced SCCHN who are unfit for high-dose cisplatin. The primary endpoint is overall survival. A total of 250 patients from 59 institutions will be enrolled over 5 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCTs031250688).
Indexed as
Antineoplastic AgentsChemoradiotherapyCisplatinHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAgedFemaleHumansMaleAntineoplastic AgentsCisplatinelderly patientshead and neck cancerradiotherapyunfit for cisplatinweekly cisplatin chemoradiotherapy
Identifiers
PMID42341154
PMCPMC13647472
What OpenQuestion holds
Textmetadata
Read underepoch 390